SARS-CoV-2-specific serological and functional T cell immune responses during acute and early COVID-19 convalescence in solid organ transplant patients
© 2021 The American Society of Transplantation and the American Society of Transplant Surgeons..
The description of protective humoral and T cell immune responses specific against SARS-CoV-2 has been reported among immunocompetent (IC) individuals developing COVID-19 infection. However, its characterization and determinants of poorer outcomes among the at-risk solid organ transplant (SOT) patient population have not been thoroughly investigated. Cytokine-producing T cell responses, such as IFN-γ, IL-2, IFN-γ/IL-2, IL-6, IL-21, and IL-5, against main immunogenic SARS-CoV-2 antigens and IgM/IgG serological immunity were tracked in SOT (n = 28) during acute infection and at two consecutive time points over the following 40 days of convalescence and were compared to matched IC (n = 16) patients admitted with similar moderate/severe COVID-19. We describe the development of a robust serological and functional T cell immune responses against SARS-CoV-2 among SOT patients, similar to IC patients during early convalescence. However, at the infection onset, SOT displayed lower IgG seroconversion rates (77% vs. 100%; p = .044), despite no differences on IgG titers, and a trend toward decreased SARS-CoV-2-reactive T cell frequencies, especially against the membrane protein (7 [0-34] vs. 113 [15-245], p = .011, 2 [0-9] vs. 45 [5-74], p = .009, and 0 [0-2] vs. 13 [1-24], p = .020, IFN-γ, IL-2, and IFN-γ/IL-2 spots, respectively). In summary, our data suggest that despite a certain initial delay, SOT population achieve comparable functional immune responses than the general population after moderate/severe COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons - 21(2021), 8 vom: 07. Aug., Seite 2749-2761 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Favà, Alexandre [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 10.08.2021 Date Revised 24.01.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/ajt.16570 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM323123112 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM323123112 | ||
| 003 | DE-627 | ||
| 005 | 20231225183511.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/ajt.16570 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1077.xml |
| 035 | |a (DE-627)NLM323123112 | ||
| 035 | |a (NLM)33756051 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Favà, Alexandre |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SARS-CoV-2-specific serological and functional T cell immune responses during acute and early COVID-19 convalescence in solid organ transplant patients |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.08.2021 | ||
| 500 | |a Date Revised 24.01.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 The American Society of Transplantation and the American Society of Transplant Surgeons. | ||
| 520 | |a The description of protective humoral and T cell immune responses specific against SARS-CoV-2 has been reported among immunocompetent (IC) individuals developing COVID-19 infection. However, its characterization and determinants of poorer outcomes among the at-risk solid organ transplant (SOT) patient population have not been thoroughly investigated. Cytokine-producing T cell responses, such as IFN-γ, IL-2, IFN-γ/IL-2, IL-6, IL-21, and IL-5, against main immunogenic SARS-CoV-2 antigens and IgM/IgG serological immunity were tracked in SOT (n = 28) during acute infection and at two consecutive time points over the following 40 days of convalescence and were compared to matched IC (n = 16) patients admitted with similar moderate/severe COVID-19. We describe the development of a robust serological and functional T cell immune responses against SARS-CoV-2 among SOT patients, similar to IC patients during early convalescence. However, at the infection onset, SOT displayed lower IgG seroconversion rates (77% vs. 100%; p = .044), despite no differences on IgG titers, and a trend toward decreased SARS-CoV-2-reactive T cell frequencies, especially against the membrane protein (7 [0-34] vs. 113 [15-245], p = .011, 2 [0-9] vs. 45 [5-74], p = .009, and 0 [0-2] vs. 13 [1-24], p = .020, IFN-γ, IL-2, and IFN-γ/IL-2 spots, respectively). In summary, our data suggest that despite a certain initial delay, SOT population achieve comparable functional immune responses than the general population after moderate/severe COVID-19 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 infection | |
| 650 | 4 | |a T cell biology | |
| 650 | 4 | |a adaptive immunity | |
| 650 | 4 | |a basic (laboratory) research / science | |
| 650 | 4 | |a clinical research / practice | |
| 650 | 4 | |a heart transplantation / cardiology | |
| 650 | 4 | |a infection and infectious agents | |
| 650 | 4 | |a kidney transplantation / nephrology | |
| 650 | 4 | |a liver transplantation / hepatology | |
| 650 | 4 | |a solid organ transplantation | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 700 | 1 | |a Donadeu, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Sabé, Nuria |e verfasserin |4 aut | |
| 700 | 1 | |a Pernin, Vincent |e verfasserin |4 aut | |
| 700 | 1 | |a González-Costello, José |e verfasserin |4 aut | |
| 700 | 1 | |a Lladó, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Meneghini, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Charmetant, Xavier |e verfasserin |4 aut | |
| 700 | 1 | |a García-Romero, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Cachero, Alba |e verfasserin |4 aut | |
| 700 | 1 | |a Torija, Alba |e verfasserin |4 aut | |
| 700 | 1 | |a Rodriguez-Urquia, Ronny |e verfasserin |4 aut | |
| 700 | 1 | |a Crespo, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Teubel, Iris |e verfasserin |4 aut | |
| 700 | 1 | |a Melilli, Edoardo |e verfasserin |4 aut | |
| 700 | 1 | |a Montero, Nuria |e verfasserin |4 aut | |
| 700 | 1 | |a Manonelles, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Preyer, Rosemarie |e verfasserin |4 aut | |
| 700 | 1 | |a Strecker, Kevin |e verfasserin |4 aut | |
| 700 | 1 | |a Ovize, Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Lozano, Juan J |e verfasserin |4 aut | |
| 700 | 1 | |a Sidorova, Julia |e verfasserin |4 aut | |
| 700 | 1 | |a Cruzado, Josep M |e verfasserin |4 aut | |
| 700 | 1 | |a Le Quintrec, Moglie |e verfasserin |4 aut | |
| 700 | 1 | |a Thaunat, Olivier |e verfasserin |4 aut | |
| 700 | 1 | |a Bestard, Oriol |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons |d 2001 |g 21(2021), 8 vom: 07. Aug., Seite 2749-2761 |w (DE-627)NLM119667924 |x 1600-6143 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2021 |g number:8 |g day:07 |g month:08 |g pages:2749-2761 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/ajt.16570 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2021 |e 8 |b 07 |c 08 |h 2749-2761 | ||